Business context and reporting period
QuidelOrtho Corporation is a global diagnostics company operating in Labs, Transfusion Medicine, Point of Care and Molecular Diagnostics. This unaudited Form 10-Q covers the 13-week quarter and 39 weeks ended October 1, 2023; comparisons are to periods ended October 2, 2022. The 2022 comparison is affected by the May 2022 Quidel-Ortho combination, so year-to-date periods do not reflect the same post-combination operating base.
Key financial metrics
Amounts in millions, except per-share data and percentages.
| Metric | Q3 2023 | Q3 2022 | Nine months 2023 | Nine months 2022 |
|---|---|---|---|---|
| Revenue | $744.0 | $783.8 | $2,255.2 | $2,399.5 |
| Operating income | $26.3 | $56.8 | $99.0 | $757.2 |
| Net income (loss) | $(12.7) | $19.2 | $(17.1) | $518.4 |
| Diluted EPS | $(0.19) | $0.28 | $(0.26) | $9.56 |
| Operating cash flow | Not provided by quarter | Not provided by quarter | $199.8 | $715.9 |
| Cash, cash equivalents and marketable securities | $205.1 at October 1, 2023 | $366.0 at January 1, 2023 | ||
| Total borrowings | $2,467.6 at October 1, 2023 | $2,638.3 at January 1, 2023 |
Gross margin, calculated from reported revenue and cost of sales excluding intangible amortization, was 49.5% in Q3 2023 versus 52.0% in Q3 2022, and 49.4% for the first nine months of 2023 versus 62.0% in 2022. Operating margin was 3.5% and 7.2% for the respective quarters, and 4.4% and 31.6% year to date. Prior-year comparisons include different combination-related costs and operating periods.
At October 1, 2023, current assets were $1,371.3 and current liabilities were $860.0. The company had $787.1 available on its $800 million revolving facility, with no revolver borrowings outstanding; $12.9 was reserved for letters of credit. It reported compliance with debt covenants. Nine-month cash flows were $199.8 provided by operations, $132.5 used in investing and $208.0 used in financing; cash, cash equivalents and restricted cash declined by $144.0.
Material changes versus the prior comparable period
- Q3 revenue fell 5%; year-to-date revenue fell 6%. Lower demand for COVID-19-related respiratory tests was the principal pressure. Q3 Point of Care revenue declined 14%, while Labs revenue increased 2% and Transfusion Medicine was roughly flat.
- For the first nine months, Point of Care revenue fell 57% and Molecular Diagnostics fell 72%. Labs and Transfusion Medicine increased 112% and 109%, respectively, primarily reflecting the combination; Labs also included a $19.2 third-party settlement award.
- Q3 net income shifted to a $12.7 loss from $19.2 income. Year-to-date results shifted to a $17.1 loss from $518.4 income. The 2022 year-to-date result is not directly comparable, including because of the combination, and the 2023 period carried higher amortization and interest costs.
- Year-to-date operating cash flow declined to $199.8 from $715.9. Collections on receivables provided $124.1, while inventory growth used $146.0 of cash. Cash and marketable securities were down $160.9 from January 1.
- Borrowings declined by $170.7 from January 1; the company paid $174.7 on its term loan, including a voluntary $20.0 prepayment. Net interest expense rose to $110.9 year to date from $41.0.
Outlook, risks and unusual items
- No numerical full-year revenue or earnings guidance is stated in the supplied filing text. Management anticipates revenue growth in core products excluding respiratory products for the remainder of 2023. Respiratory demand is expected to fluctuate, with continuing price pressure and seasonal effects from cold, flu and RSV demand.
- Management says supply, production, logistics, distribution and labor challenges improved during 2023 but may persist and could affect the ability to manufacture and deliver products. Other uncertainties include inflation, foreign exchange, interest rates, competition, integration and realization of combination synergies, and changing respiratory-disease demand.
- The company expects cash, operating cash flow and revolver availability to cover near-term operating and capital needs for at least 12 months. Planned needs include debt service, manufacturing capacity, R&D, integration and commercialization. A five-year warehouse lease with approximately $36 million in payments is expected to commence in late 2023 or early 2024.
- Unusual or notable items include a $19.2 settlement award in Labs revenue; an approximately $39 million reduction in inventory obsolescence reserves during the first nine months; and $105.8 transferred from instrument inventories to property and equipment. The filing says a change in estimating retail COVID-19 test returns had no material financial-statement impact.
- Legal matters include product liability, commercial, intellectual property, regulatory and other proceedings. Management does not expect current matters in aggregate to have a material adverse effect, but notes that resolution or increased accruals could materially affect results or cash flows. The filing reports no material change in previously disclosed risk factors.
- Foreign exchange translation reduced comprehensive income by $17.2 year to date; the quarter included a $55.3 translation loss. Variable-rate debt creates interest-rate exposure, partly hedged through swaps. Management reported disclosure controls effective at a reasonable-assurance level.
Important facts for investors to verify
- How quickly declining COVID-19 test demand and respiratory product pricing affect revenue, margins and cash generation.
- Whether core-product growth, combination synergies and integration benefits offset lower respiratory sales and the higher cost base.
- Inventory levels, the sustainability of the reserve estimate change, and the cash impact of inventory accumulation and instrument placements.
- Debt repayment capacity, interest expense and covenant headroom, including the impact of variable rates as interest-rate swaps change or expire.
- Seasonal respiratory demand, supply-chain constraints, the warehouse lease commencement and any material developments in legal or tax contingencies.